Review

Medical therapy for nephrolithiasis: State of the art

Igor Sorokin a, Margaret S. Pearle b,c,∗

a Department of Urology, University of Massachusetts, Worcester, MA, USA
b Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA
c Charles and Jane Pak Center for Mineral Metabolism and Bone Research, UT Southwestern Medical Center, Dallas, TX, USA

Received 14 January 2018; received in revised form 8 April 2018; accepted 11 July 2018
Available online 3 September 2018

KEYWORDS
Medical management; Kidney stones; Medical therapy; Pharmacology; Nephrolithiasis

Abstract The prevalence of nephrolithiasis is increasing worldwide. Understanding and implementing medical therapies for kidney stone prevention are critical to prevent recurrences and decrease the economic burden of this condition. Dietary and pharmacologic therapies require understanding on the part of the patient and the prescribing practitioner in order to promote compliance. Insights into occupational exposures and antibiotic use may help uncover individual risk factors. Follow-up is essential to assess response to treatment and to modify treatment plans to maximize therapeutic benefit.

© 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

It is estimated that 50% of symptomatic kidney stone events could be prevented by addressing modifiable risk factors that can reduce the burden of stone disease on the general population [1,2]. Unfortunately, medical management strategies are underused and inconsistent [3]. The high prevalence and recurrent nature of kidney stones contribute to the large economic burden on society related to stone disease. Indeed, in 2000 the cost of stone disease to the United States health care system was estimated at $5 billion [4]. This is further compounded by the cost of missed work by working-age adults, who are disproportionately afflicted by stone disease compared with children or the elderly. Estimates from the Urologic Diseases in America project in 2012 suggest the cost is now up to $10 billion, making stone disease one of the most expensive urologic conditions [5]. The cost of stone disease has been predicted to rise to more than $15 billion by 2030 as a consequence of population growth and the rising prevalence of obesity and diabetes, both risk factors for stone disease [6]. Furthermore, stone disease significantly affects individual well-being, with lower quality of life (QoL) demonstrated even in those with asymptomatic stones [7].

https://doi.org/10.1016/j.ajur.2018.08.005
2214-3882/© 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Department of Urology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-09110, USA.
E-mail address: margaret.pearle@utsouthwestern.edu (M.S. Pearle).
Peer review under responsibility of Second Military Medical University.
Both the American Urologic Association (AUA) [8] and the European Association of Urology (EAU) [9] published recent guidelines on the prevention of recurrent nephrolithiasis, with specific recommendations regarding evaluation and dietary and pharmacologic therapy. The purpose of this state-of-the-art review is to examine strategies of medical management according to the latest published evidence and in accordance with recent guidelines. In addition, we will highlight recent efforts to improve compliance and QoL in patients with recurrent kidney stones.

2. Epidemiology

Nephrolithiasis is a highly prevalent disease worldwide with rates ranging from 7%—13% in North America, 5%—9% in Europe, and 1%—5% in Asia [10]. In the United States, there has been a linear increase in stone prevalence over the last 4 decades, with the prevalence in women rising disproportionately compared with men. While traditionally men have demonstrated a higher prevalence of stone disease than women, the gender gap is narrowing [11,12]. However, the difference in prevalence between men and women is not consistent worldwide, with male to female ratios varying from 2.7 to 4 among populations in Germany, Saudi Arabia, and China (Taiwan) [10].

The most common stone composition is calcium-based (70%—85%), followed by uric acid (5%—10%), struvite (1%—5%), and cystine (1%) [13], although one community found calcium stones present in 93.5% of kidney stone formers [14]. In a retrospective review of 1516 patients at a single-institution from 1980 to 2015, the proportion of uric acid stones increased from 7% to 14%, with uric acid stone formers consistently older and with a higher body mass index (BMI) than calcium stone formers [15]. While calcium stones remain common, analyzing stone composition remains beneficial to identify non-calcium stone formers, who tend to have higher rates of recurrence and require specific preventive strategies.

3. Screening evaluation

In addition to the common potential sequelae associated with kidney stones, such as pain, infection and obstruction, nephrolithiasis is also considered a risk factor for chronic kidney disease [16]. As such, a thorough screening evaluation to identify patients with kidney stones who are at high risk of recurrence is prudent. The screening evaluation includes a detailed medical and dietary history, serum chemistries, urinalysis, stone analysis, and imaging studies. Those identified as high risk stone formers are then targeted for further metabolic testing with 24-hour urine collections to identify modifiable urinary risk factors that can be corrected with diet and medication.

A detailed medical history is aimed at identifying conditions associated with stone disease such as primary hyperparathyroidism, distal renal tubular acidosis (RTA), gout, metabolic syndrome, type 2 diabetes, obesity and malabsorptive gastrointestinal disorders. Metabolic syndrome is estimated to affect 25% of adults in the U.S. and is associated with a 30% increase in risk of nephrolithiasis [17]. Gastrointestinal disorders associated with chronic diarrhea, such as intestinal resection, pancreatic insufficiency, celiac sprue, Crohn’s disease and ulcerative colitis cause predictable urinary abnormalities that lead to stone formation. A history of first-time versus recurrent stones also helps to stratify risk. In addition, some medications are associated with stone disease either by altering urinary analytes in an unfavorable way (topiramate, acetazolamide, zonisamide) or by direct precipitation of the drug or its metabolites in the urine (trimethadione, ciprofloxacin). Finally, a detailed dietary history involving fluid intake, salt use, animal protein consumption and supplement use can reveal dietary risk factors for stone formation.

Serum chemistries should include calcium, creatinine, potassium, bicarbonate and uric acid, as abnormal values may suggest underlying medical conditions associated with stone disease, such as high serum calcium and primary hyperparathyroidism, or low serum bicarbonate and potassium and high chloride implicating distal RTA. Serum intact parathyroid hormone is considered an optional test that is indicated when primary hyperparathyroidism is suspected, such as when serum calcium is high or high normal, urinary calcium is exceptionally high, or with pure calcium phosphate stone composition. Urine should be evaluated by dipstick and microscopic analysis, as low or high pH can raise suspicion for uric acid (pH < 5.5) or infection stones (pH > 7), respectively, and the presence of bacteria and/or pyuria can implicate infection stones.

Radiographic imaging provides a baseline assessment of stone burden and can reflect the level of metabolic activity. Multiple stones on initial imaging, even with a first stone event, imply recurrent stone disease. Nephrocalcinosis is typically associated with either anatomic anomalies (medullary sponge kidney) or medical conditions associated with recurrent stones, such as primary hyperparathyroidism or distal RTA.

Environmental exposures, the so-called exposome, may contribute to nephrolithiasis and comprise potential targets for modification [18]. High risk occupations that involve excessive heat exposure or conditions that preclude adequate hydration because of lack of access to water or bathroom facilities predispose to stone formation. In a survey of healthcare professionals, physicians working in an operating room setting were found to have the highest prevalence of nephrolithiasis (17.4%) and reported lower fluid intake and higher stress levels [19]. A recent study of 100 steel workers noted a stone prevalence of 16%, with dehydration, defined as urine osmolality >700 mOsm, noted in 57% of workers by the end of their work shift [20]. Welders and spray painters have also been reported to have a higher risk of stone disease as a result of exposure to nephrotoxic agents contained in paint, such as cadmium and oxalic acid [10]. Overuse of antibiotics may lower colony counts of Oxalobacter formigenes, a stone-protective bacterium that uses intestinal oxalate as its sole substrate [18]. Living in urban environments may enhance stone risk because of exposure to warmer areas created by lack of vegetation and effects of urban architecture [18].

All patients who have formed stones can benefit from general dietary counseling. However, for those in whom the screening evaluation identifies factors associated with an increased risk of stone recurrence, national guidelines support further metabolic testing with one or two 24 h
urine collections [8,9]. While some have criticized 24 h urine testing for its complexity, inconvenience, cost, and limited ability to predict recurrence [21], spot urine collections, and particularly the spot calcium-to-creatinine ratio, have been shown to be inferior to 24 h urine samples, but are sometimes used in children or other individuals for whom 24 h urine testing is impractical or impossible [22]. A 12 h nighttime urine collection has recently been proposed as an alternative to 24 h urine testing because it showed a strong correlation with 24 h collections but was less cumbersome for patients [23]. Further studies are needed to validate this simplified urine collection. While imperfect, the 24 h urine still remains the best tool to assess specific modifiable urinary stone risk factors.

4. Dietary management

Diet modification is an inexpensive, safe, and proven method to improve lithogenic risk factors and should be considered alone or along with pharmacotherapy for idiopathic calcium oxalate stone formers. A variety of dietary factors can be targeted for modification to reduce stone formation, including increasing fluids, maintaining normal calcium intake, limiting foods rich in oxalate, consuming sodium and animal protein in moderation and enriching the diet in fruits and vegetables (Table 1). Specific dietary measures based metabolic testing and follow-up have been shown to be more successful than general dietary recommendations and no specific testing in preventing recurrent stones [24]. One study recommended that practitioners prioritize dietary recommendations, as three or few recommendations are associated with higher patient recall [25].

4.1. Fluids

High fluid intake is recommended in all stone formers, regardless of stone composition, because it has been shown to be beneficial and cost effective [26]. A long-term randomized controlled trial (RCT) among recurrent idiopathic calcium oxalate stone formers demonstrated that a fluid intake of at least 2 L/day reduced the risk of stone recurrence by about 56% [27]. A recent meta-analysis evaluating the effect of high fluid intake on recurrent stone formation revealed a pooled risk ratio (RR) of 0.40 (95%CI: 0.20—0.79, p = 0.008) among two RCTs comprising 269 patients and 0.49 (95%CI: 0.34—0.71, p = 0.0002) among seven observational studies comprising 273 685 patients [28]. A fluid intake under 2 L/day was also recently shown to be the strongest risk factor for incident stone formation among male health care professionals (40–75 years old) enrolled in the longitudinal Health Professionals Follow-up Study (HPFS) [1]. The AUA Medical Management of Kidney Stones Guideline recommends a fluid intake that will yield a urine output of at least 2.5 L/day for stone formers, and even more (3 L/day) for higher risk groups such as patients with cystinuria [8].

Table 1

| Dietary component | Recommendation |
|-------------------|----------------|
| Fluid             | Maintain fluid intake that achieves urine volume ≥2.5 L daily Limit sugar-sweetened soft drinks Consider intake of orange juice with no added sugar to prevent calcium nephrolithiasis |
| Calcium           | Avoid severe dietary calcium restriction Maintain calcium intake of 1000–1200 mg/day |
| Oxalate           | Avoid oxalate rich foods (nuts, chocolate, brewed tea, spinach, rhubarb, beets, potatoes, peanut butter, wheat bran, beans) Avoid juices with cranberry, grapefruit, starfruit Maintaining normal calcium intake is beneficial |
| Protein           | Moderately restrict animal protein (red meat, fish, poultry, pork, shellfish) to no more than 6–8 ounces daily |
| Carbohydrate      | Restrict refined carbohydrates to <20 g/day |
| Sodium            | Limit sodium intake to ≤100 mEq/day (2300 mg/day) Increase intake of fruits and vegetables, orange juice is beneficial |
| Citrate           | Consider for enteric hyperoxaluria (take with the two largest meals) but avoid for idiopathic calcium stone disease if dietary calcium intake is sufficient |
| Calcium supplement| Consider for primary hyperoxaluria type 1, but not proven for idiopathic causes |
| Vitamin B6 supplement | Limit intake of vitamin C to <2 g/day |
| Vitamin C supplement | Should not be withheld solely on the basis of stone disease. If deficient and repletion is indicated, monitor with 24 h urine analysis. |
| Vitamin D supplement | Avoid (increase in net acid; hypocitraturia; hypercalciuria, hyperuricosuria) |
| Low carbohydrate/high protein diet (Atkins) | Likely protective against stone disease |
| DASH diet          | Likely protective against stone disease (inferred from similarities to DASH diet) |
| Mediterranean diet | Likely protective against stone disease |

DASH, dietary approaches to stop hypertension.

The benefit of fluids other than water has been investigated less vigorously. Large epidemiologic studies of both men and women showed a reduced risk of incident stone formation with coffee, tea, beer, red wine and orange juice, while sugar sweetened beverages were associated with an increased risk of stone formation [29]. A consensus statement by a multidisciplinary group of stone experts
recommended against the consumption of sugar-sweetened beverages and encouraged intake of orange juice with no added sugar as potential measures to protect against calcium nephrolithiasis [16]. The effect of lemonade is controversial. Although a small, uncontrolled metabolic study [30] and two retrospective studies [31,32] showed a beneficial effect with regard to increasing urinary citrate and reducing recurrent stone formation, two controlled, metabolic studies showed that orange juice and potassium citrate, but not lemonade, promoted a citraturic response [33,34].

Increased fluid intake has not proven to be a simple recommendation with which to comply [25]. A questionnaire designed to estimate the success of achieving a high fluid intake among 302 stone formers noted perceived higher success rates in patients who preferred water and liked the “taste” of plain water compared to other beverages [35]. The most common barrier to increasing fluid intake was noted to be “not feeling thirsty” (44.2%), followed by frequent urination (32.8%) and difficulty drinking while at school or work (20.7%). Using a container to carry water was noted to be a key strategy for success in maintaining a high fluid intake compared to simply making an effort to remember to drink. Compliance may be further improved with technologies such as “smart” water bottles that can accurately quantify 24 h fluid intake [36].

4.2. Calcium

Hypercalciuria is the most common risk factor among calcium oxalate stone formers [37]. Hypercalciuria has been variously defined as 24 h urinary calcium >300 mg/day in men, >250 mg/day in women or >200 mg/day in either sex while on a diet restricted in calcium, sodium, and animal protein [38,39]. Hypercalciuria may be a manifestation of systemic diseases such as primary hyperparathyroidism or sarcoidosis, but is considered idiopathic if no underlying cause can be identified. While idiopathic hypercalciuria has been shown to have a genetic predisposition in some cases, it can also be influenced by environmental factors such as diet [40]. Although kidney stone formers have a higher risk of bone fracture than those in the general population [41], it is not clear that hypercalciuria is a cause. In a retrospective study of 250 men and 182 post-menopausal women on or off estrogen therapy, no significant relationship was found between urine calcium levels and bone mineral density. Hypercalciuria may not cause low bone mineral density and increased fracture rate among stone formers [42].

A normal calcium intake (1 000–1 200 mg/day elemental calcium or approximately three servings of dairy daily) is recommended for patients with idiopathic hypercalciuria [8,9]. Both dairy and non-dairy dietary sources of calcium have been shown to have a protective effect against incident stone formation [43]. On the other hand, severe calcium restriction should be avoided as it may accelerate bone loss and lead to hyperoxaluria due to the interaction between calcium and oxalate in the intestinal lumen by which calcium binds to oxalate and forms a calcium oxalate complex. In the setting of low calcium intake, excess uncomplexed oxalate is absorbed, ultimately leading to increased urinary oxalate excretion [37,44,45].

Calcium in the form of food is preferred over calcium supplements as supplementation has been shown in epidemiologic studies to be associated with an increased risk of incident stone formation [46–48]. If calcium supplements are indicated, they should be taken with meals, allowing the ingested calcium to complex with oxalate, thereby reducing intestinal oxalate absorption and counteracting the effect of increased urinary calcium.

Vitamin D deficiency has been shown to be more prevalent in the stone-forming population [49]. However, repletion of vitamin D with supplements in this population has been controversial. The Women’s Health Initiative study demonstrated a 17% increased risk of stone formation among 36 282 postmenopausal women randomized to calcium carbonate plus vitamin D (1 000 mg/day and 400 IU/day, respectively) versus placebo [50]. However, a recent small RCT comparing 6 weeks of low (1 000 IU/day) versus high (50 000 IU weekly) dose vitamin D supplementation among 21 vitamin D deficient stone formers found no significant change in urinary calcium after treatment in either group, although only the higher dose group showed a significant increase in serum vitamin D levels [51]. If vitamin D repletion is indicated, urine calcium should be monitored with 24 h urine studies [52,53].

4.3. Oxalate

Hyperoxaluria occurs in approximately 10%–15% of calcium stone formers. Increased urinary oxalate can occur as a consequence of excessive dietary intake, endogenous oxalate overproduction or intestinal oxalate overabsorption. In normal individuals, approximately 10% of ingested oxalate is absorbed while the rest is eliminated through the stool [54,55]. For reasons not clearly understood, calcium oxalate stone formers absorb a slightly higher proportion of oxalate from the intestine than do normal subjects [54]. Oxalate absorption depends not only on the amount of dietary oxalate, but also on dietary calcium intake. Higher calcium diets lead to reduced oxalate absorption, while calcium-restricted diets are associated with enhanced oxalate absorption and subsequently increased urinary oxalate excretion [55,56]. As such, a normal calcium diet in association with oxalate restriction is recommended in hyperoxaluric patients. High oxalate foods such as spinach, rhubarb, beets, nuts, chocolate, potatoes, bran, legumes and tea should be avoided [57]. Some juices have been found to have a high oxalate content, including cranberry [58], grapefruit [59] and carambola juice (starfruit) [60]. Spinach is frequently added to homemade fruit and vegetable juices, raising the oxalate content [61]. Since the leaves are not cooked or processed to enhance removal or reduction of soluble oxalate, this practice may pose a threat to calcium oxalate stone formers. The addition of small amounts of calcium ions, especially in the form of calcium chloride, has been recommended by some to convert the oxalate into an insoluble form that is less likely to be absorbed in the digestive tract [61]. However, any added calcium should be considered when calculating total dietary calcium intake.

Interestingly, no studies have directly shown a correlation between urinary oxalate and recurrent idiopathic calcium
oxalate stone formation, and therefore recommendation of dietary oxalate restriction is empiric. Indeed, Noori and colleagues [62] randomized 57 patients with hyperoxaluria and recurrent calcium oxalate stones to a low oxalate diet or to the Dietary Approaches to Stop Hypertension (DASH) diet, which is a diet high in fruits, vegetables, nuts and legumes (high oxalate content) and low in sodium and red and processed meats. Although urinary oxalate increased in the group assigned to the DASH diet and decreased in those adhering to a low oxalate (4.8 mg/day vs. −4.2 mg/day, respectively, \( p = 0.08 \)), urinary saturation of calcium oxalate declined more on the DASH diet (−2.14) than on the low oxalate diet (−0.90, \( p = 0.08 \)), suggesting that other dietary measures had greater impact on reducing urinary stone risk than a low oxalate diet.

Enzymatic defects in the oxalate biosynthetic pathway lead to markedly high levels of urinary oxalate leading to aggressive calcium oxalate stone formation and oxalosis. Among the three forms of primary hyperoxaluria (I—III), renal failure is typically seen only with primary hyperoxaluria type I. Strict dietary oxalate restriction is recommended in all forms of primary hyperoxaluria [63].

Patients with malabsorptive disorders from intestinal resection, roux-en-Y gastric bypass surgery, Crohn’s disease, celiac sprue, pancreatitis or use of fat-malabsorbing medications such as orlistat [64], are at risk of enteric hyperoxaluria because luminal calcium binds to poorly absorbed fatty acids, leading to higher levels of uncomplexed oxalate that is subsequently absorbed and excreted in the urine. In these patients, strict dietary oxalate restriction, along with a low fat diet and use of calcium supplements with meals to bind luminal oxalate is an effective strategy for stone prevention.

Finally, O. formigenes is a Gram-negative anaerobic bacterium that resides in the intestine and uses oxalate as its sole source for energy and growth [65]. Animal models have shown that absence of O. formigenes colonization can result in reduced degradation of oxalate in the intestinal lumen as well as reduced enteric oxalate secretion [66]. Other animal models demonstrated that colonization with O. formigenes in addition to a low fat diet decreased urinary oxalate excretion [67]. A case-control study in human subjects noted that despite a strong inverse correlation between colonization and risk of recurrent stone formation, no significant difference in median urinary oxalate levels was detected between patients who were or were not colonized with O. formigenes [68]. Further work is needed to clarify the therapeutic role of this organism or its enzymes in preventing calcium oxalate stone formation.

4.4. Citrate

Hypocitraturia has been reported in 15%–63% of patients with kidney stones and is often seen in conjunction with other metabolic disorders [69]. Citrate is an important inhibitor of calcium stone formation because it directly inhibits nucleation, agglomeration and growth of calcium oxalate and/or calcium phosphate crystals and by complexing with calcium to reduce urinary saturation of calcium salts [70]. Renal citrate excretion is modulated primarily by acid–base status; acidosis increases citrate reabsorption and alkalsis enhances citrate production and excretion in the renal proximal tubule.

Fruits and vegetables increase urinary citrate because of their high alkali content, but not all fruits and juices have the same citratric effect. Orange juice has shown the most consistent benefit because it has a high content of potassium citrate that confers an alkali load [33,71,72]. Lemonade, which is high in citric acid, does not affect urine pH and has less citratric effect. While fruit juices offer a more palatable and less costly therapy than potassium citrate medication, fruit juices can be high in calories and oxalate content and this may temper their use [59,73]. Fruits with a high malic acid (precursor to citrate) content, such as pears, may theoretically increase urinary citrate but few studies have examined this [74]. Unfortunately, no citrus fruits or juices have been tested in a randomized trial to assess their benefit in reducing stone recurrence rates.

The DASH diet, as an overall healthy diet, has been suggested to reduce the rate of stone formation [75]. The high alkali content, among other factors, may contribute to improvement in urinary stone risk factors [76]. Among three large cohorts of both men and women [Nurses’ Health Study I (NHS I), Nurses’ Health Study II (NHS II), and HPFS], those subjects adhering most closely to the DASH diet had the lowest risk of incident stone formation on multivariate analysis [1]. That is to say, when patients were given a score relating to how closely their diet resembled the DASH diet, those in the lowest quintile of DASH scores had the highest rate of incident stone formation in HPFS (odds ratio (OR) = 1.53, 95% CI: 1.31–1.78), NHS I (OR = 1.47, 95% CI: 1.25–1.73), and NHS II (OR = 1.37, 95% CI: 1.21–1.55).

4.5. Sodium

Lowering salt intake is essential for stone prevention. Sodium increases stone risk by increasing urinary calcium excretion and decreasing urinary citrate [77,78]. Sodium-induced calcium excretion is further compounded by animal protein-induced hypercalciuria [79]. Along with ample fruits and vegetables, reduction of sodium intake is a primary component of the DASH diet and likely contributes to its lower stone risk [75].

The AUA guideline recommends limiting sodium intake to no more than 2 300 mg/day. Healthy middle-aged women from the NHS I cohort who had a daily sodium intake in the highest quintile (median sodium intake 4 958 mg/day) demonstrated a higher risk of incident stone disease [46]. However, the same correlation did not hold true in NHS II, the cohort of younger nurses, or in the cohort of men in HPFS [47,48]. In two RCTs evaluating the effect of a low sodium diet on hypercalciuric stone formers, the groups randomized to a low sodium diet demonstrated lower mean urinary calcium excretion [80] or lower rate of stone recurrence [81] than the control groups.

4.6. Protein

Uric acid is the metabolic end product of purine metabolism and animal protein is a rich source of purines. Urinary uric acid has been shown to reduce the effectiveness of naturally occurring macromolecular inhibitors of calcium oxalate
crystallization [82]. In addition, protein derived from animal sources increases stone risk by increasing urinary calcium and oxalate and reducing pH and citrate. Animal protein provides an acid load through the high content of sulfur-containing amino acids, which leads to a state of mild chronic metabolic acidosis, low urine pH and hypocitraturia [83,84]. Since high protein diets are often additionally devoid of sufficient fruits and vegetables, hypocitraturia may also ensue from the lack of alkali [85]. Interestingly, a study comparing idiopathic calcium stone formers with a control group found a higher mean renal acid load in the stone formers, even though animal protein intake was similar between the two groups [86]. The authors attributed these findings to a lower intake of fruits and vegetables among stone formers. Furthermore, a small metabolic study simulating the three phases of the Atkins diet (a low carbohydrate, high protein diet) demonstrated increases in urinary uric acid and calcium and decreases in pH and citrate during both the stringent induction phase and the less stringent maintenance phases of the diet compared to baseline [87]. While the acid load conferred by animal protein has been presumed to promote hypercalciuria by increasing bone resorption [88], Maalouf and colleagues [89] found that administration of potassium citrate failed to prevent protein-induced hypercalciuria, suggesting that the hypercalciuria may be attributable to a renal etiology.

The recommended dietary allowance of protein is 0.8 g/kg/day [90], and animal protein restriction should include all forms of meat, including beef, poultry, and fish. A 3-phase randomized, crossover metabolic study in 25 normal subjects comparing three different animal protein sources revealed higher levels of urinary uric acid during the fish phase compared to the beef or poultry phase, although urinary saturation of calcium oxalate did not simply reflect urinary uric acid levels [91]. Additionally, the question often arises among stone patients whether ingestion of whey protein, a dairy-derived protein supplement popular among athletes because it is thought to increase muscle mass and improve exercise performance, is also a risk factor for stone formation. A recent 2-phase metabolic study in which whey protein or albumin was given to 18 healthy volunteers on a controlled diet for 3 days showed no significant change from baseline in urinary stone risk factors with either supplement [92].

5. Pharmacologic management

When dietary measures fail or are inappropriate in patients with particular metabolic backgrounds, pharmacotherapy may be indicated to reduce stone recurrence (Table 2). A recent systematic review and meta-analysis of 21 RCTs comprising 2168 participants determined that drug therapy was more effective than dietary therapy in preventing stone recurrence among recurrent idiopathic calcium stone formers [93]. Of note, the benefit of therapy was apparent only among those with two or more previous stone episodes. Although multiple RCTs have shown a benefit of pharmacotherapy in preventing stone recurrence, compliance with prescribed drug regimen is often suboptimal. Using medical claims data, Dauw and colleagues [94] found that only 30.2% of kidney stone patients who were prescribed medications for stone prevention adhered to their drug regimen. Factors that were independently associated with lower likelihood of adherence included combination drug therapy, female gender, less comprehensive health insurance and residence in the South or Northeast of United States. Older patients and salaried employees had a higher probability of adherence. Interestingly, adherence rates differed according to the prescribed drug, with only 13% of patients complying with citrate therapy compared to 42.5% for thiazides and 40% for allopurinol.

5.1. Calcium stones

5.1.1. Thiazides

Thiazide diuretics are recommended by both the AUA and EAU guidelines for patients with recurrent calcium-based stones and hypercalciuria [8,9]. Thiazides enhance calcium reabsorption directly in the distal renal tubule and indirectly in the proximal renal tubule. A meta-analysis of six RCTs found that thiazides were associated with a 47% relative risk reduction in stone recurrence rates compared with placebo or no treatment [95]. The benefit of thiazides may additionally extend to normocalciuric patients since the proportion of patients with documented hypercalciuria in these RCTs was variable, and indeed in some trials the metabolic background of patients was unknown.

Thiazide doses and regimens tested in RCTs include hydrochlorothiazide 25 mg twice daily, chlorthalidone 25 mg daily or indapamide 2.5 mg daily. Interestingly, one study noted that only 35% of patients treated with thiazides were prescribed a dose shown in RCTs to be beneficial for stone prevention [96]. The most common side effect of thiazides is hypokalemia, which may lead to hypocitraturia due to intracellular acidosis. As such, potassium supplementation is recommended to prevent hypokalemia, to avoid increased cardiovascular risk and to minimize glucose intolerance. The choice of potassium citrate versus potassium chloride to prevent thiazide-induced hypokalemia should be based on initial or follow-up urine pH and citrate; whether either is low, potassium citrate may be the preferred potassium supplement.

Because hypercalciuria has been shown to be a risk factor for osteoporosis, a multidisciplinary panel of stone experts authored a consensus paper in which they recommended that stone formers at increased risk of bone loss undergo measurement of bone mineral density by dual emission X-ray absorptiometry (DXA) [16]. The fracture risk associated with stone disease varies by skeletal site and demonstrates a higher risk of incident wrist fracture, but not hip fracture, in women and men [97]. The use of thiazides in hypercalciuric men was shown to reduce urinary calcium and improve bone mineral density in a short-term study [98]. Likewise, Pak and colleagues [99] observed significant increases in bone mineral density at the lumbar spine, femoral neck and radial shaft in 28 recurrent idiopathic hypercalciuric stone formers treated with thiazides and potassium citrate for a mean of 3.7 years.

5.1.2. Potassium citrate

Potassium citrate is used to correct hypocitraturia, which occurs alone or in combination with other abnormalities in about 10%–60% of calcium stone formers [100]. Barcelo and
coworkers [101] showed a benefit of potassium citrate therapy among 57 recurrent, hypocitraturic calcium stone formers randomized to receive either 30–60 mEq of potassium citrate daily or placebo in a 3-year trial assessing stone remission rates. Patients in the potassium citrate group had a significantly higher remission rate compared to the placebo group (72% vs. 20%, respectively, RR = 0.25, 95%CI: 0.09–0.70). Potassium citrate has also been shown to improve stone remission rates after shock wave lithotripsy. A recent meta-analysis evaluated the efficacy of potassium citrate in reducing stone recurrence rates 12 months after shock wave lithotripsy in four trials comprising 374 participants [102]. A significantly lower stone recurrence rate was seen 12 months after shock wave lithotripsy in the potassium citrate group compared to the control group (RR = 0.21, 95%CI: 0.13–0.31). Finally, patients with hypocitraturia due to distal RTA have also been shown to benefit from potassium citrate therapy, as the alkali load corrects the metabolic acidosis, increases urinary citrate excretion and reduces stone recurrence rates [103].

Potassium citrate may also reduce urinary calcium excretion as an additional benefit of treatment. Song and associates [104] observed a mean decrease in urine calcium of 30% among 22 hypocitraturic calcium oxalate stone formers receiving 30–60 mEq of potassium citrate daily for at least 3 months. They speculated that the reduction in urinary calcium may be accounted for by a decrease in bone turnover due to systemic alkalinization, by binding of calcium by citrate in the intestine and reducing calcium absorption or as a result of a direct effect on the distal renal tubule affecting calcium reabsorption. The optimal dose and formulation of potassium citrate remains to be determined [70]. However, potassium citrate is usually administered as a sustained-release wax matrix

| Medication          | Rationale                        | Dose                                      | Specifics/side effects                          | Monitoring                  |
|---------------------|----------------------------------|-------------------------------------------|------------------------------------------------|----------------------------|
| **Calcium oxalate stones** |                                 |                                           |                                                 |                            |
| Thiazide            | Hypercalciuria                    | Hydrochlorothiazide 25–50 mg BID, chlorthalidone 25–50 mg/day, indapamide 1.25–5 mg/day | Hypokalemia, hyperlipidemia, hyperuricemia, hyperglycemia, hypocitraturia, hyperuricosuria, fatigue, erectile dysfunction | BMP, uric acid, lipid profile |
| **Potassium citrate** | Hypocitraturia, low urine pH      | 10–30 mEq BID                             | GI side effects                                 | Serum creatinine & potassium |
| (oral)              | Enteric hyperoxaluria, chronic diarrhea | 15–30 mEq TID–QID (titrate to reduce oxalate) | GI side effects, take with two largest meals Hypertransaminasemia, Stevens–Johnson syndrome | Serum creatinine & potassium |
| **Allopurinol**     | Hyperuricosuria                   | 100–300 mg/day                            | Hypertransaminasemia, Stevens–Johnson syndrome  | Liver enzymes               |
| **Uric acid stones** | Alkalization                      | 10–30 mEq BID (titrate dose to pH 6–6.5)  | GI side effects                                 | Serum creatinine & potassium |
| **Sodium bicarbonate** | Alkalization                    | 650 mg BID–QID                            | Increased sodium load may increase risk of calcium stones Hypertransaminasemia, Stevens–Johnson syndrome | BMP                        |
| **Allopurinol**     | Hyperuricosuria 2nd line therapy when alkalinization not successful | 100–300 mg/day | Hypertransaminasemia, Stevens–Johnson syndrome | Liver enzymes               |
| **Cystine stones**  | Increase cystine solubility       | Initial 400 mg/day titrate to effect      | Hematologic effects, tachyphylaxis, proteinuria, nausea, diarrhea, vitamin B6 deficiency (long-term use) | CBC, BMP, urine protein     |
| Tiopronin (α-MPG)   |                                   |                                           |                                                 |                            |
| Potassium citrate   | Alkalization                      | 10–30 mEq BID (titrate dose to pH 7–7.5)  | GI side effects                                 | Serum creatinine & potassium |
| (oral)              |                                   |                                           |                                                 |                            |
| **Struvite stones** | Urease-inhibitor                  | 250 mg BID–TID                            | Headache, anemia, thrombophlebitis, rash, tremulousness | CBC                       |

BMP, basic metabolic profile; CBC, complete blood count; GI, gastrointestinal; MPG, mercaptopropionyl glycine.  
First-line therapy.
tablet in doses ranging from 10–30 mEq twice daily. However, for patients with chronic diarrhea, use of a liquid formulation is advised because the rapid intestinal transit in these patients precludes sufficient absorption of sustained-release potassium citrate [105].

The most common side effects of potassium citrate are gastrointestinal upset, abdominal pain, and diarrhea. Taking the medication with meals may prevent these symptoms in some patients. Periodic monitoring with serum electrolytes and creatinine is recommended. For patients at risk of hyperkalemia or those who are unable to tolerate potassium citrate, sodium alkali such as sodium bicarbonate or a combination of sodium citrate and citric acid may be considered, although the sodium load conferred by these medications may induce hypercalciuria.

5.1.3. Allopurinol

Hyperuricosuria is seen in approximately 20% of patients with calcium stones [106]. Although dietary restriction of animal protein is recommended as first line therapy in patients with hyperuricosuria, allopurinol, a xanthine oxidase inhibitor that lowers serum and urinary uric acid, is indicated in patients who are unable to normalize urinary uric acid with diet alone or in those with a genetic predisposition to hyperuricosuria. Allopurinol may additionally have antioxidant effects that contribute to the prevention of calcium stone formation, independent of xanthine oxidase inhibition [107]. Among four RCTs evaluating the effect of allopurinol in recurrent calcium oxalate stone formers, the only trial to show a significant benefit in reducing recurrence rates is one in which only hyperuricosuric, normocalciuric patients were enrolled [108].

Allopurinol is generally well tolerated but may, in rare cases, be associated with Stevens–Johnson syndrome. Any patient reporting a rash with allopurinol should be instructed to discontinue the medication immediately. Hypertransaminasemia is another side effect that is generally reversible with discontinuation of the medication. Liver enzymes should be monitored soon after starting allopurinol and periodically thereafter [109].

5.1.4. Pyridoxine

Nondiuretic urinary oxalate is derived from the conversion of glyoxylate to oxalate by the enzyme lactate dehydrogenase [110,111]. Pyridoxine, a component of vitamin B6, is a necessary cofactor for alanine:glyoxylate aminotransferase (AGT) which is involved in the alternate metabolic conversion of glyoxylate to glycine. Patients with primary hyperoxaluria type I have a deficiency in AGT by which they are unable to divert glyoxylate metabolism to the alternate pathway. While the only curative treatment for this disease is liver transplantation, pyridoxine can be used to decrease urinary oxalate. A prospective, uncontrolled open label trial in which 12 patients with primary hyperoxaluria type I were given pyridoxine incrementally up to a dosage of 20 mg/kg per day showed a 25.5% mean relative reduction in urinary oxalate, with benefit seen in 50% of patients [112].

Pyridoxine has been proposed as a preventative treatment in patients with idiopathic hyperoxaluria as well. One retrospective study evaluating the effect of pyridoxine on urinary oxalate in 95 idiopathic hyperoxaluric stone formers found that 75% of patients treated with pyridoxine and dietary counseling versus only 52% of patients treated with dietary counseling alone showed a reduction in urinary oxalate [113]. On the other hand, three large cohort studies (HPFS, NHS I, NHS II) found no association between vitamin B6 intake and risk of incident kidney stones [114]. The AUA Medical Management of Kidney Stones Guideline found insufficient evidence to recommend pyridoxine for the management of patients with idiopathic hyperoxaluria [8]. However if it is used, pyridoxine should be started at a low dose and titrated in a stepwise fashion to no more than 200 mg/day [115]. Doses exceeding 500 mg/day should be avoided because of the risk of developing severe sensory neuropathy.

5.2. Non-calcium based stones

5.2.1. Uric acid stones

Uric acid stones account for approximately 10% of all kidney stones in the United States [116]. Low urine pH is the primary risk factor for idiopathic uric acid nephrolithiasis, although low urine volume and hyperuricosuria are additional contributors. Gout is a well-established risk factor for pure uric acid stones due to a defect in renal production of ammonia leading to acidic urine [117]. Additionally, uric acid stones have recently been observed to comprise a greater proportion of stones among individuals with metabolic syndrome, type 2 diabetes, or obesity due to a defect in ammoniagenesis as well as increased net acid excretion, both of which lead to acidic urine [118]. One study noted that metabolic syndrome conferred a 93% increased OR of forming uric acid stones, particularly in those with higher fasting serum glucose and hypertriglyceridemia [119].

The prevention of uric acid stone formation involves the administration of alkali to increase urine pH. A target pH of 6–6.5 can effectively prevent and dissolve uric acid stones [120]. Potassium citrate, titrated to achieve the target pH, is first-line therapy for uric acid stone formers, with sodium alkali (sodium bicarbonate) reserved for those unable to tolerate potassium citrate or for whom renal dysfunction or hyperkalemia precludes its use. Of note, even large amounts of uric acid are soluble if the urine pH is sufficiently high; in contrast, even small amounts of uric acid will precipitate out in acidic urine. As such, allopurinol should not constitute first line therapy for idiopathic uric acid stone formers and is reserved only for patients who continue to form uric acid stones despite adequate urinary alkalinization [8]. In addition to pharmacologic treatment to prevent uric acid stones, lifestyle changes such as weight loss and exercise should be recommended by physicians for patients with metabolic syndrome.

Dissolution therapy for uric acid stones is also achievable with alkali therapy using a target urine pH of 6–6.5. However, the success of dissolution therapy relies on accurate diagnosis of pure uric acid stones. One group of investigators determined that computed tomography (CT) Hounsfield units ≤500, pH ≤5.5 and stone size > 4 mm on non-enhanced CT had an 86% sensitivity, 98% specificity, and 90% positive predictive value for diagnosing uric acid stones [121]. In an in vivo study of 30 patients, dual energy CT was shown to have a 100% positive predictive value for detecting uric acid stones [122]. Patients with 100% pure uric acid stones tend to be older (60 vs. 55 years, \( p = 0.05 \)), heavier (34.3 vs. 29 kg/m²),
5.2.2. Cystine stones
Cystinuria is a rare inherited disorder in the renal and intestinal transport of the dibasic amino acids, caused by mutations in the SLC3A1 and/or SLC7A9 genes [126]. The worldwide prevalence of cystinuria is estimated at 1:7000, although it is regionally variable [127]. The hallmark of cystinuria is aggressive and recurrent cystine stone formation stemming from defective cystine reabsorption in the proximal tubule, leading to accumulation of poorly soluble cystine in the urine.

The therapeutic goal in treating patients with cystinuria is to reduce cystine concentration or raise cystine solubility above the solubility limit of 250 mg/L. Reducing cystine concentration can be accomplished with increased fluid intake, typically enough fluid intake to produce a urine volume of at least 3 L/day, or by reducing cystine excretion. Restriction of sodium and animal protein have been shown in randomized trials to decrease urinary cystine excretion [128–130]. Like all stone formers, cystinuric patients are advised to limit their sodium intake to less than 2300 mg/day (100 mEq/day) [8].

Cystine solubility is influenced by urine pH and the presence of urinary macromolecules. Because cystine solubility increases significantly only above pH 7.5 and most cystinuric patients have high urine pH at baseline, urinary alkalinization has a limited therapeutic role, but constitutes second line therapy after diet and fluids, with the goal of treatment to achieve a urine pH of 7.0–7.5. At pH > 7, the risk of calcium phosphate stone formation becomes more pronounced, and repeat stone analysis, if one is available during treatment, should be pursued [131,132]. Potassium alkali (potassium citrate) is preferred over sodium alkali for urinary alkalinization because sodium enhances urinary cystine excretion.

For more severe cystinuria, cystine-binding thiol drugs (CBTD) constitute third line therapy [133,134]. Agents most commonly used include α-mercaptopyrropropionyl glycine (tiopronin) and α-penicillamine. Thiol compounds contain sulfhydryl groups that undergo a disulfide exchange reaction with cystine to produce two molecules of cysteine bound to the CBTD, a complex that is 50 times more soluble than cystine. The effect of the drugs is dose-dependent.

Tiopronin, as a second generation CBTD, is considered the first line drug, with dosing starting at 200 mg two or three times daily and titrated to achieve a urine cystine concentration of less than 250 mg/L. Adverse effects include fever, gastrointestinal upset, asthenia, rash, joint aches, loss of taste, thrombocytopenia, aplastic anemia, proteinuria, and changes in mental status [135].

α-penicillamine has a more extensive side effect profile than tiopronin and therefore is used much less commonly [136]. Dosing typically starts at 250 mg two or three times daily and is titrated to effect. One study reported adverse effects in 65% of patients taking tiopronin compared with 84% of those taking α-penicillamine [137]. Adverse reactions necessitating cessation of treatment were also less common with tiopronin (31% vs. 69%, respectively). Long-term therapy with α-penicillamine may lead to pyridoxine (vitamin B6) deficiency, which may require oral supplementation (50 mg/day).

Captopril is a third generation angiotensin-converting-enzyme inhibitor that also contains a free sulfhydryl group and has been shown in vitro to increase cystine solubility [138]. However, the recommended doses of captopril in vivo are not thought to be sufficient to induce a therapeutic effect on cystine stone formation and the drug has not been tested in rigorous clinical trials.

Recently, a widely available nutritional supplement, α-lipoic acid, has been investigated as a treatment for cystinuria [139]. Using the SLC3A1−/− mouse model which grows urinary bladder stones at a rate of 1 mm3/day, treatment with α-lipoic acid was found to not only attenuate growth of existing cystine stones but also prevent initiation of new stone formation. The protective effect is thought to be derived from increased urinary cystine solubility due to excretion of downstream α-lipoic acid metabolites into the urine. Clinical trials are necessary to prove its efficacy in humans.

Although traditionally the goal of treatment has been to reduce urinary cystine concentration below the solubility level [133], most assays are unable to distinguish free cystine from soluble thiol drug-cysteine complexes. A proprietary test, cystine capacity (Litholink Corporation, Chicago, IL, USA), has been shown to reliably estimate stone forming propensity even in the presence of CBTDs and offers an alternative means of monitoring therapeutic efficacy [140,141].

5.2.3. Struvite stones
Struvite stones form as a consequence of repeated infection with urease-producing organisms, leading to alkaline urine and precipitation of magnesium ammonium phosphate crystals. Because these stones incorporate bacteria inside them, aggressive surgical stone removal is essential to eradicate the bacteria and prevent recurrent infections and stone. Culture-specific antibiotic therapy is recommended both pre-operatively and for some time post-operatively to sterilize the urine and prevent re-infection. A recent multi-institutional study on patterns of infection and colonization of struvite stones revealed that the bacteriology has shifted away from traditional urea-splitting organisms such as Proteus to Enterococcus and Escherichia coli [142]. The high prevalence of infection with Enterococcus (18%) suggests that 1st and 2nd generation cephalosporins may be ineffective and antibiotic coverage should include agents appropriate for Enterococcus. Nonetheless, there is a lack of evidence on the role of antibiotics in preventing stone growth/recurrence and the optimal duration of therapy.

Acetohydroxamic acid (AHA), a potent urease inhibitor, decreases the risk of struvite stone formation by preventing bacterial-induced urease from altering the urinary milieu. AHA has been shown in a number of RCTs to reduce stone growth and prolong the time interval to stone
growth [143–145]. However, adverse events are common, leading to high attrition rates. Side effects include tremor, palpitations, edema, proteinuria, headache, rash, alopecia, anemia, gastrointestinal discomfort, and thromboembolic phenomena. In light of these limitations, acetohydroxamic acid, along with suppressive antibiotics, are reserved for patients at high risk of recurrent struvite stone formation and/or those unable to undergo surgical stone removal. Using a lower dose of 250 mg twice daily has been proposed to reduce the overall adverse events, although deep vein thrombosis/pulmonary embolus was still prevalent [146].

6. Follow-up

The success of a medical prophylactic program hinges on improvement in urinary stone risk factors and ultimately on reduction in stone recurrence rate. By monitoring 24 h urine parameters, a change in stone risk might be anticipated and corrected before stones recur. The frequency of follow-up depends on the metabolic activity of the individual. Periodic imaging can detect failure of medical therapy and prompt early surgical treatment and modulation of the medical regimen. In addition, follow-up should include blood and urine testing for adverse effects of treatment, such as hypokalemia with thiazides or proteinuria with α-mercaptopropionyl glycine (tiopronin).

7. Conclusion

A thorough evaluation to identify the underlying causes of stone disease is necessary to direct medical therapy. A screening evaluation to identify those at risk and further metabolic testing in those at higher risk optimizes the diagnostic algorithm. While imperfect, 24 h urine testing remains the best available tool to identify urinary stone risk factors and direct medical and dietary therapy. Phamacotherapy is reserved for patients who fail dietary therapy or who have demonstrable metabolic abnormalities that are not amenable to dietary therapy. Treatment plans should be designed to minimize cost and maximize compliance and effectiveness. Finally, follow-up is essential to assess response to treatment and to modify treatment plans to maximize therapeutic benefit.

Author contributions

Study concept: Igor Sorokin.
Search for articles: Igor Sorokin, Margaret S. Pearle.
Review and inclusion of articles: Igor Sorokin.
Drafting of manuscript: Igor Sorokin.
Critical revision of the manuscript: Margaret S. Pearle.

Conflicts of interest

The authors declare no conflict of interest.

References

[1] Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Dietary and lifestyle risk factors associated with incident kidney stones in men and women. J Urol 2017;198:858–63.
[2] Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) registry. Kidney Int 2005;67:1053–61.
[3] Milose JC, Kaufman SR, Hollenbeck BK, Wolf Jr JS, Hollingsworth JM. Prevalence of 24-hour urine collection in high risk stone formers. J Urol 2014;191:376–80.
[4] Saigal CS, Joyce G, Timilsina AR. Urolologic Diseases in America Project. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int 2005;68:1808–14.
[5] Litwin MS, Saigal C. Urolologic diseases in America. Washington, DC: US Government Printing Office; 2012.
[6] Antonelli JA, Maalouf NM, Pearle MS, Lotan Y. Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol 2014;66:724–9.
[7] Penniston KL, Sninsky BC, Nakada SY. Preliminary evidence of decreased disease-specific health-related quality of life in asymptomatic stone patients. J Endourol 2016;30(Suppl 1):542–5.
[8] Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denucciaca CJ, Mattiaga BR, et al. Medical management of kidney stones: AUA guideline. J Urol 2014;192:316–24.
[9] Skolarikos A, Straub M, Knoll T, Sarika K, Seitz C, Petrik A, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 2015;67:750–63.
[10] Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol 2017;35:1301–20.
[11] Scales Jr CD, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol 2012;62:160–5.
[12] Scales Jr CD, Curtis LH, Norris RD, Springhart WP, Sur RL, Schulman KA, et al. Changing gender prevalence of stone disease. J Urol 2007;177:979–82.
[13] Knoll T, Schubert AB, Fahlenkamp D, Leusmann DB, Wendt-Nordahl G, Schubert G. Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. J Urol 2011;185:1304–11.
[14] Singh P, Enders FT, Vaughan LE, Bergstralh EJ, Knoedler JJ, Krambeck AE, et al. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc 2015;90:1356–65.
[15] Xu LHR, Adams-Huet B, Poindexter JR, Maalouf NM, Moe OW, Sakhaee K. Temporal changes in kidney stone composition and in risk factors predisposing to stone formation. J Urol 2017;197:1465–71.
[16] Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worchester E, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 2016;29:715–34.
[17] DiBianco JM, Jarrett TW, Mufarrij P. Metabolic syndrome and intervention of the medical regimen. In addition, follow-up should include blood and urine testing for adverse effects of treatment, such as hypokalemia with thiazides or proteinuria with α-mercaptopropionyl glycine (tiopronin).

7. Conclusion

A thorough evaluation to identify the underlying causes of stone disease is necessary to direct medical therapy. A screening evaluation to identify those at risk and further metabolic testing in those at higher risk optimizes the diagnostic algorithm. While imperfect, 24 h urine testing remains the best available tool to identify urinary stone risk factors and direct medical and dietary therapy. Pharmacotherapy is reserved for patients who fail dietary therapy or who have demonstrable metabolic abnormalities that are not amenable to dietary therapy. Treatment plans should be designed to minimize cost and maximize compliance and effectiveness. Finally, follow-up is essential to assess response to treatment and to modify treatment plans to maximize therapeutic benefit.

Author contributions

Study concept: Igor Sorokin.
Search for articles: Igor Sorokin, Margaret S. Pearle.
Review and inclusion of articles: Igor Sorokin.
Drafting of manuscript: Igor Sorokin.
Critical revision of the manuscript: Margaret S. Pearle.

Conflicts of interest

The authors declare no conflict of interest.

References

[1] Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Dietary and lifestyle risk factors associated with incident kidney stones in men and women. J Urol 2017;198:858–63.
Medical therapy for urolithiasis

[22] Jones AN, Shafer MM, Keuler NS, Crane EM, Hansen KE. Fasting and postprandial spot urine calcium-to-citrate ratios do not detect hypercalciuria. Osteoporos Int 2012;23:553–62.

[23] Hinck BD, Ganesan V, Tarplin S, Asplin J, Granja I, Calle J, et al. Can a simplified 12-hour nighttime urine collection predict urinary stone risk? Urology 2017;108:40–5.

[24] Fritsche HM, Dotzer K. Improving the compliance of the recurrent stone-former. Arab J Urol 2012;10:342–6.

[25] Penniston KL, Wertheim ML, Nakada SY, Jhagroo RA. Factors associated with patient recall of individualized dietary recommendations for kidney stone prevention. Eur J Clin Nutr 2016;70:1062–7.

[26] Lotan Y, Buendia Jimenez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, et al. Increased water intake as a prevention strategy for recurrent urolithiasis: major impact of compliance on cost-effectiveness. J Urol 2013;189:935–9.

[27] Borgh L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839–43.

[28] Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium oxalate stone formers: a randomized controlled trial. J Urol 2017;197:1079–83.

[29] Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013;8:1389–95.

[30] Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 1996;156:907–9.

[31] Penniston KL, Steele TH, Nakada SY. Lemonade therapy in idiopathic stone formers, but does correction pose any risk? Kidney Int 1998;53:459.

[32] Bhattacharya S, Sopassathit W, Stitchantrakul W, Domrongkitchaiporn S, Flocchini A, Lauretani F. Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. J Urol 2017;197:1472–7.

[33] Taylor EN, Curhan GC. Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones. J Urol 2013;190:1255–9.

[34] Hess B, Jost C, Zipperle L, Takkinen R, Jaeger P. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998;13:2241–7.

[35] Domrongkitchaiporn S, Sakhaee K, Maalouf NM, Poindexter J, Adams-Huet B. Factors associated with patient recall of individualized dietary recommendations for kidney stone prevention. Eur J Clin Nutr 2016;70:1062–7.

[36] Lotan Y, Buendia Jimenez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, et al. Increased water intake as a prevention strategy for recurrent urolithiasis: major impact of compliance on cost-effectiveness. J Urol 2013;189:935–9.

[37] Borgh L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839–43.

[38] Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium oxalate stone formers: a randomized controlled trial. J Urol 2017;197:1079–83.

[39] Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013;8:1389–95.

[40] Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 1996;156:907–9.

[41] Penniston KL, Steele TH, Nakada SY. Lemonade therapy in idiopathic stone formers, but does correction pose any risk? Kidney Int 1998;53:459.

[42] Bhattacharya S, Sopassathit W, Stitchantrakul W, Domrongkitchaiporn S, Flocchini A, Lauretani F. Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. J Urol 2017;197:1472–7.

[43] Taylor EN, Curhan GC. Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones. J Urol 2013;190:1255–9.

[44] Hess B, Jost C, Zipperle L, Takkinen R, Jaeger P. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998;13:2241–7.

[45] Domrongkitchaiporn S, Sakhaee K, Maalouf NM, Poindexter J, Adams-Huet B. Factors associated with patient recall of individualized dietary recommendations for kidney stone prevention. Eur J Clin Nutr 2016;70:1062–7.

[46] Lotan Y, Buendia Jimenez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, et al. Increased water intake as a prevention strategy for recurrent urolithiasis: major impact of compliance on cost-effectiveness. J Urol 2013;189:935–9.

[47] Borgh L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839–43.

[48] Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium oxalate stone formers: a randomized controlled trial. J Urol 2017;197:1079–83.

[49] Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013;8:1389–95.

[50] Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 1996;156:907–9.

[51] Penniston KL, Steele TH, Nakada SY. Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation. Urology 2007;70:856–60.

[52] Kang DE, Sur RL, Haleblain GE, Fitzsimons NJ, Borawski KM, Preminger GM. Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol 2007;177:1358–62.

[53] Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 2006;1:1269–74.

[54] Koff SG, Paquette EL, Cullen J, Gancarczyk KK, Tucciarone PR, Schenkman NS. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology 2007;69:1013–6.

[55] Tarplin S, Monga M, Stern KL, McCauley LR, Sarkissian C, Nguyen MM. Predictors of reporting success with increased fluid intake among kidney stone patients. Urology 2016;88:49–56.

[56] Borofsky MS, Dawu CA, York N, Terry C, Lingeman JE. Accuracy of daily fluid intake measurements using a “smart” water bottle. Urolithiasis 2018;46:343–8.

[57] Sakhaee K, Maalouf NM, Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 2012;97:1847–60.

[58] Worcester EM, COE FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008;28:120–32.

[59] Pak CY, Sakhaee K, Moe OW, Poindexter J, Adams-Huet B, Pearle MS, et al. Defining hypercalciuria in nephrolithiasis. Kidney Int 2011;80:777–82.

[60] COE FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med 1979;300:337–40.

[61] Melton 3rd LS, Crowson CS, Khoury J, S. Wilson DM, O’Fallon WM. Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 1998;53:459–64.

[62] Sakhaee K, Maalouf NM, Poindexter J, Adams-Huet B, Moe OW. Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. J Urol 2017;197:1472–7.

[63] Taylor EN, Curhan GC. Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones. J Urol 2013;190:1255–9.
controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis 2014;63:456–63.

[63] Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol 2012;8:467–75.

[64] Solomon LR, Nixon AC, Ogden L, Nair B. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Rep 2017;2017.

[65] Allison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 1985;141:1–7.

[66] Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006;69:691–8.

[67] Canales BK, Hatch M. Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria. Surg Obes Relat Dis 2017;13:1152–7.

[68] Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008;19:1197–77.

[69] Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol 2009;11:134–44.

[70] Phillips R, Chanhanale VS, Myatt A, Somani B, Nabi G, Biyani CS. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev 2015, CD010057.

[71] Honow R, Laube N, Schneider A, Kessler T, Hesse A. Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization. Br J Nutr 2003;90:295–300.

[72] Wabner CL, Pak CY. Effect of orange juice consumption on urinary stone risk factors. J Urol 1993;149:1405–8.

[73] Tracy CR, Pearle MS. Update on the medical management of stone disease. Curr Opin Urol 2009;19:200–8.

[74] Manfredini R, De Giorgi A, Storari A, Fabbian F. Pears and renal stones: possible weapon for prevention? A comprehensive narrative review. Eur Rev Med Pharmacol Sci 2016;20:414–25.

[75] Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009;20:2253–9.

[76] Taylor EN, Stampfer MJ, Mount DB, Curhan GC. DASH-style diet and 24-hour urine composition. Clin J Am Soc Nephrol 2010;5:2315–22.

[77] Massey LK, Whiting SJ. Dietary salt, urinary calcium, and kidney stone risk. Nutr Rev 1995;53:131–9.

[78] Sakhaee K, Harvey JA, Padalino PK, Whitson P, Pak CY. The potential role of salt abuse on the risk for kidney stone formation. J Urol 1993;150:310–2.

[79] Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the kidney disease. BMJ Case Rep 2017;2017.

[80] Nouvenne A, Ticinesi A, Morelli I, Guida L, Borghi L, Meschi T. Fad diets and their effect on urinary stone formation. Transl Androl Urol 2014;3:303–12.

[81] Vezzoli G, Dogliotti E, Terranegra A, Arcidiacono T, Macrina L, Tavecchia M, et al. Dietary style and acid load in an Italian population of calcium kidney stone formers. Nutr Metab Cardiovasc Dis 2015;25:588–93.

[82] Reddy ST, Wang CY, Sakhaee K, Brinkley L, Pak CY. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002;40:265–74.

[83] Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc 1995;95:791–7.

[84] Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal-protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988;66:140–6.

[85] Nouvenne A, Tiricavesi A, Morelli I, Guida L, Borghi L, Meschi T. Fad diets and their effect on urinary stone formation. Transl Androl Urol 2014;3:303–12.

[86] Vezzoli G, Dogliotti E, Terranegra A, Arcidiacono T, Macrina L, Tavecchia M, et al. Dietary style and acid load in an Italian population of calcium kidney stone formers. Nutr Metab Cardiovasc Dis 2015;25:588–93.

[87] Reddy ST, Wang CY, Sakhaee K, Brinkley L, Pak CY. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002;40:265–74.

[88] Buclin T, Cosma M, Appenzeller M, Jacquet AF, Decosterd LA, Biollaz J, et al. Diet acids and alkalis influence calcium retention in bone. Osteoporos Int 2001;12:493–9.

[89] Maalouf NM, Moe OW, Adams-Huet B, Sakhaee K. Hyperoxaluria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab 2011;96:3733–40.

[90] Eisenstein J, Roberts SB, Dalal G, Saltzman E. High-protein weight-loss diets: are they safe and do they work? A review of the experimental and epidemiologic data. Nutr Rev 2002;60:189–200.

[91] Tracy CR, Best S, Bagrodia A, Poindexter JR, Adams-Huet B, Sakhaee K, et al. Animal protein and the risk of kidney stones: a comparative metabolic study of animal protein sources. J Urol 2014;192:137–41.

[92] Hattori CM, Tiselius HG, Helberg IP. Whey protein and albumin effects upon urinary risk factors for stone formation. Urolithiasis 2017;45:421–8.

[93] Ferraro PM, Curhan GC, D’Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol 2017;30:227–33.

[94] Dauw CA, Yi Y, Bierlein MJ, Yan P, Alruwaily AF, Ghani KR, et al. Factors associated with preventive pharmacological therapy adherence among patients with kidney stones. Urolithiasis 2016;93:45–9.

[95] Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 2013;158:535–43.

[96] Vigen R, Weideman RA, Reilly RF. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol 2011;43:813–9.

[97] Taylor EN, Feskanich D, Pak JM, Curhan GC. Nephrolithiasis and risk of incident bone fracture. J Urol 2016;195:1482–6.

[98] Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 1999;130:658–60.

[99] Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD. Prevention of stone formation and bone loss in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 1999;130:658–60.

[100] Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995;98:50–9.

[101] Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:203–4.

[102] Carvalho M, Erbano BO, Kuwaki EY, Pontes HP, Liu J, Boros LH, et al. Effect of potassium citrate supplement on stone recurrence before or after lithotripsy: systematic review and meta-analysis. Urolithiasis 2017;45:449–55.
Medical therapy for urolithiasis

[103] Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985;134:20–3.

[104] Song Y, Hernandez N, Shoag J, Goldfarb DS, Eihsner BH. Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis. Urolithiasis 2016;44:145–8.

[105] Sakhaee K, Pak C. Superior calcium bioavailability of effervescent potassium citrate over tablet formulation of calcium citrate after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2013;9:743–8.

[106] Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalcuiuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 1977;87:404–10.

[107] Arowojolu O, Goldfarb DS. Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. J Nephrol 2014;27:601–5.

[108] Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 1999;13:679–85.

[109] Morgan MS, Pearle MS. Medical management of renal stones. BMJ 2016;352:i52.

[110] Holmes RP, Assimos DG. Glyoxylate synthesis, and its modulation in oxalate synthesis, and its modulation in oxalate excretion. J Urol 1989;141:742–7.

[111] Lindell A, Denneberg T, Edholm E, Jeppsson JO. The effect of dietary protein on cystine excretion in patients with cystinuria. J Urol 1989;141:819–21.

[112] Williams HE, Wandzilak TR. Antioxidants and the hyperoxaluric syndromes. J Urol 1989;141:742–7.

[113] Ortiz-Alvarado O, Miyaoaka R, Kriedberg C, Moeding A, Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Williams HE, Wandzilak TR. Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 1989;141:742–7.

[114] Bonatti M, Lombardo F, Zamboni GA, Pernter P, Pycha A, Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Novel insights into the pathogenesis of oxuric acid nephrolithiasis. Curr Opin Nephrol Hypertens 2004;13:181–9.

[115] Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS. Effect of acetohydroxamic acid in struvite nephrolithiasis. J Urol 1989;141:819–21.

[116] Morgan MS, Pearle MS. Medical management of renal stones. BMJ 2016;352:i52.

[117] Raichand C, Gill BC, Sarkissian C, De S, Manga M. 100% urinary calcium stone formers: what makes them different? Urology 2015;95:296–8.

[118] Trinchieri A, Esposito N, Castelnuovo C. Dissolution of radiolucent renal stones by oral alkalinization with potassium citrate/potassium bicarbonate. Arch Ital Urol Androl 2009;81:188–91.

[119] Sinha M, Prabhu K, Venkatesh P, Krishnamoorthy V. Results of urinary dissolution therapy for radiolucent calculi. Int Braz J Urol 2013;39:103–7.

[120] Ng CS, Streem SB. Contemporary management of cystinuria. J Endourol 1999;13:647–51.

[121] Knoll T, Zolnier A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 2005;20:19–24.

[122] Jaeger P, Portmann L, Saunders A, Rosenberg LE, Thier SO. Anticystineuric effects of glutamine and of dietary sodium restriction. N Engl J Med 1986;315:1120–3.

[123] Lindell A, Danneberg T, Edholm E, Jeppsson JO. The effect of sodium intake on cystinuria with and without tiopronin treatment. Nephron 1995;71:407–15.

[124] Rodman JS, Blackburn P, Williams JJ, Brown A, Pospischil MA, Peterson CM. The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol 1984;22:273–8.

[125] Pak CY, Pointdexter JR, Pak CY. The spectrum of metabolic abnormalities in patients with cystine nephrolithiasis. J Urol 1989;141:819–21.

[126] Arowojolu O, Goldfarb DS, Evans AP, Worcester EM. Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant 2009;24:130–6.

[127] Barkey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P. Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 2000;163:1419–23.

[128] Park BH, Cho FL, Evans AP, Worcester EM. Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant 2009;24:130–6.

[129] Saravacos P, Kokkinou V, Giannatos E. Cystinuria: current diagnosis and management. Urol 2014;83:693–9.

[130] Thiola [package insert on the internet]. San Antonio, TX: Mission Pharmacal Company; 2018. [Accessed 1 July 2018]. http://www.thiola.com/pdf/Thiola%20PI.pdf.

[131] DeBerardinis RJ, Coughlin 2nd CR, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 2008;180:2620–3.

[132] Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 1986;136:1003–8.

[133] Zhao J, Izzo Jr JL. Captopirin reduces urinary cystine excretion in cystinuria. Arch Intern Med 1987;147:1409–12.

[134] Zee T, Bose N, Zee J, Beck JN, Yang S, Parikh J, et al. Alphalipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria. Nat Med 2017;23:288–90.

[135] Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 2006;69:1041–7.

[136] Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS. Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol 2005;19:429–32.

[137] Parkhomenko E, De Fazio A, Tran T, Thai J, Blum K, Gupta M. A multi-institutional study of struvite stones: patterns of infection and colonization. J Endourol 2017;31:533–7.

[138] Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 1991;20:243–7.

[139] Williams JJ, Rodman JS, Peterson CM. A randomized double-blind study of acetyohydroxamic acid in struvite nephrolithiasis. N Engl J Med 1984;311:760–4.

[140] Griffith DP, Khonsari F, Skurnick JH, James KE. A randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 1991;20:243–7.

[141] Williams JJ, Rodman JS, Peterson CM. A randomized double-blind study of acetyohydroxamic acid in struvite nephrolithiasis. N Engl J Med 1984;311:760–4.

[142] DeBerardinis RJ, Coughlin 2nd CR, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 2008;180:2620–3.

[143] Parkhomenko E, De Fazio A, Tran T, Thai J, Blum K, Gupta M. A multi-institutional study of struvite stones: patterns of infection and colonization. J Endourol 2017;31:533–7.

[144] Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 1991;20:243–7.

[145] Williams JJ, Rodman JS, Peterson CM. A randomized double-blind study of acetyohydroxamic acid in struvite nephrolithiasis. N Engl J Med 1984;311:760–4.